Cytochrome P450 knockout mice: New toxicological models

Clinical and Experimental Pharmacology and Physiology

Volumn 25, Issue 10, 1998, Pages 783-787

  McKinnon, Ross A ^a   Nebert, Daniel W ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Cyp1a2; Cyp2e1; Cytochrome P450; Gene targeting; Toxicological models

Indexed keywords

CYTOCHROME P450; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; GENE CONTROL; GENE MUTATION; GENE TARGETING; HOMEOSTASIS; KNOCKOUT MOUSE; MOUSE; NONHUMAN; REVIEW; TOXICITY; XENOBIOTIC METABOLISM;

EID: 0031712338     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1998.tb02153.x     Document Type: Review

References (38)

1. Nelson DR, Koymans LO, Kamataki T et al. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
2. Nebert DW. Drug-metabolizing enzymes in ligand-modulated transcription. Biochem. Pharmacol. 1994; 47: 25-37.
3. Pineau T, Fernandez-Salguero P, Lee STT, McPhail T, Ward JM, Gonzalez FJ. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 CYP1A2. Proc. Natl Acad. Sci. USA 1995; 92: 5134-8.
4. Liang H-C, Li H, McKinnon RA et al. Cyp1a2 (-/-) null mutant mice develop normally, but show deficient drug metabolism. Proc. Natl Acad. Sci. USA 1996; 93: 1671-6.
5. Lee SST, Buters JTM, Pineau T, Fernandez.-Salguero P, Gonzalez FJ. Role of Cyp2e1 in the hepatoxicity of acetaminophen. J. Biol. Chem. 1996; 271: 12 063-7.
6. Capecchi MR. The new mouse genetics: Altering the genome by gene targeting. Trends Genet. 1989; 5: 70-6.
7. Bronson SK, Smithies O. Altering mice by homologous recombination using embryonic stem cells. J. Biol. Chem. 1994; 269: 27 155-8.
8. Nelson DR, Kamataki T, Waxman DJ et al. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names, and nomenclature. DNA Cell Biol. 1993; 12: 1-51.
9. Hildebrand CE, Gonzalez FJ, Kozak CA, Nebert DW. Regional linkage analysis of the dioxin-inducible P-450 gene family on mouse chromosome 9. Biochem. Biophys. Res. Commun. 1985; 130: 396-406.
10. Nebert DW, Gonzalez FJ. P450 genes: Structure, evolution and regulation. Annu. Rev. Biochem. 1987; 56: 945-93.
11. Poland AP, Glover E, Taylor BA. The murine Ah locus: A new allele and mapping to chromosome 12. Mol. Pharmacol. 1988; 32: 471-8.
12. Swanson HI, Bradfield CA. The AH receptor: Genetics, structure and function. Pharmacogenetics 1993; 3: 213-30.
13. McKinnon RA, Hall P de la M. Quattrochi LC, Tukey RH, McManus ME. Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 1991; 14: 848-56.
14. Guengerich FP, Shimada T, Raney KD et al. Elucidation of catalytic specificities of human cytochrome P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology. Environ. Health Perspect. 1992; 98: 75-80.
15. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993; 3: 239-49.
16. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics 1995; 5: 259-74.
17. Lambrecht RW, Sinclair PR, Gorman N, Sinclair JF. Uroporphyrinogen oxidation catalyzed by reconstituted cytochrome P450IA2. Arch. Biochem. Biophys. 1992; 294: 504-10.
18. Sinclair PR, Gorman N, Dalton T et al. Uroporphyria produced in mice by iron and 5-aminolevulinic acid does not occur in Cyp1a2(-/-) null mutant mice. Biochem. J. 1998; 330: 149-53.
19. Nebert DW, Duffy JJ. How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction, development, and environmental toxicity, cancer and oxidative stress. Biochem. Pharmacol. 1997; 53: 249-54.
20. Siblia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995; 269: 234-8.
21. Threadgill DW, Glugosz AA, Hansen LA et al. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 1995; 269: 230-4.
22. Bedell MA, Jenkins NA, Copeland NG. Good genes in bad neighbourhoods. Nature Genet. 1996; 12: 229-32.
23. Milot E, Fraser P, Grosveld F. Position effects and genetic disease. Trends Genet. 1996; 12: 123-6.
24. Olson EN, Arnold H-H, Rigby PWJ, Wold BJ. Know your neighbours. Three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell 1996; 85: 1-4.
25. Bonyadi M, Rusholme SAB, Cousins FM et al. Mapping of a major genetic modifier of embryonic lethality in TGFβ1 knockout mice. Nature Genet. 1997; 15: 207-11.
26. Simpson EM, Linder CC, Sargent EE, Davisson MT, Mobraaten LE, Sharp JJ. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nature Genet. 1997; 16: 19-27.
27. Liang HC, McKinnon RA, Nebert DW. Sensitivity of CYP1A1 mRNA inducibility is the same in Cyp1a2(+/+) wild-type and Cyp1a2(-/-) null mutant mice. Biochem. Pharmacol. 1997; 54: 1127-31.
28. Buters JTM, Tang BK, Pineau T, Gelboin HV, Kimura S, Gonzalez FJ. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: Studies using mice deficient in CYP1A2. Pharmacogenetics 1996; 6: 291-6.
29. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 1991; 4: 168-79.
30. Valentine JL, Lee SST, Seaton MJ et al. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicol. Appl. Pharmacol. 1996; 141: 205-13.
31. Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: The second decade. Cell 1995; 83: 835-9.
32. Fernandez-Salguero P, Pineau T, Hubert DM et al. Immune system impairment and hepatic fibrosis in mice lacking the aryl-hydrocarbon receptor. Science 1995; 268: 722-6.
33. Lee SST, Pineau T, Drago J et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell Biol. 1995; 15: 3012-22.
34. Schmidt JV, Su GH-T, Reddy JK, Simon MC, Bradfield CA. Characterisation of murine Ahr null allele: Involvement of the receptor in hepatic growth and development. Proc. Natl Acad. Sci. USA 1996; 93: 6731-6.
35. Nebert DW, Puga A, Vasiliou V. Role of the Ah receptor and the dioxin-inducible (Ah) gene battery in toxicity, cancer, and signal transduction. Ann. N.Y. Acad. Sci. 1993; 685: 624-40.
36. Nebert DW, McKinnon RA. Cytochrome P450: Evolution and functional variability. Prog. Liver Dis. 1994; 14: 1-31.
37. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P450 1B1 (CYP1B1] as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. 1997; 6: 641-7.
38. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K. Deletion of a DNA polymerase β gene segment in T cells using cell type-specific gene targeting. Science 1994; 265: 103-6.